Isofol Medical AB (ISOFOL) AI Stock Analysis

• Market Cap: kr236.75M
• Dividend Yield: N/A
• Average Volume (3M): 1.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.21
• Revenue Growth: -100.00%
• EPS Growth: -17.35%
• Country: SE
• Employees: 5
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 269,192,400
• 10 Day Avg. Volume: 1,041,448
• 30 Day Avg. Volume: 1,173,050
• PEG Ratio: 0.02
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 36 Underperform
• Price Target: ―

Isofol Medical AB's overall stock score reflects substantial financial challenges and speculative valuation typical of early-stage biotech firms. The lack of revenue growth, significant losses, and negative cash flows are key concerns, despite a strong equity position with zero debt. Technical indicators suggest a mixed trend, with some recent upward momentum but long-term bearish signals. The speculative nature of the stock results in a low overall score, highlighting the need for strategic transitions towards profitability.

Isofol Medical AB Business Overview & Revenue Model

Company Description

Isofol Medical AB (ISOFOL) is a pharmaceutical company focused on developing oncology treatments. Headquartered in Sweden, the company is dedicated to improving the efficacy and safety of standard chemotherapy drugs. Its core product, arfolitixorin, is designed to enhance the effectiveness of folate-based cancer therapies, particularly in colorectal cancer. Isofol Medical aims to advance cancer care through innovative pharmaceutical solutions, addressing unmet medical needs in the oncology sector.

How the Company Makes Money

Isofol Medical AB generates revenue primarily through the development and commercialization of its lead product, arfolitixorin. Revenue streams include licensing agreements, collaborations with pharmaceutical companies, and potential sales upon regulatory approval. The company engages in strategic partnerships to facilitate research, development, and distribution, which contribute to its earnings. Additionally, Isofol may receive milestone payments and royalties from partner collaborations, further supporting its financial model. The company's focus on oncology treatments positions it to benefit from the growing demand for cancer therapies globally.

Isofol Medical AB Financial Statement Overview

Summary

Isofol Medical AB's financial statements reveal significant challenges, typical of biotechnology companies in R&D phases. The income statement shows declining revenues and substantial net losses. Despite a strong equity position with zero debt, the balance sheet highlights a decreasing equity base, and cash flows are negative, indicating ongoing cash burn. These factors underscore the need for strategic financial management to achieve sustainability.

Income Statement

Isofol Medical AB has faced declining revenues over the years, with zero revenue reported in the most recent year. The company continues to incur significant losses, as evidenced by its negative net profit margin and EBIT margin. The gross profit margin is also negative, indicating high operational costs relative to revenue. Overall, the income statement underscores substantial financial challenges and a lack of revenue growth, which is typical in early-stage biotechnology companies focused on R&D.

Balance Sheet

The balance sheet reveals a relatively strong equity position with zero debt, leading to a favorable debt-to-equity ratio. However, total assets have been declining, and stockholders' equity has decreased over recent years. The equity ratio signifies a solid proportion of assets funded by equity, which is a positive sign of financial stability. Despite this, the continuous reduction in equity highlights potential concerns about long-term sustainability.

Cash Flow

Isofol Medical AB reports negative operating and free cash flows, indicating ongoing cash burn, a common scenario for biotechnology firms in the R&D phase. The operating cash flow to net income ratio is challenging to assess due to consistent negative net income. The lack of positive cash flow growth further suggests reliance on external financing to sustain operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	721.00K	12.80M	22.41M	37.12M
Gross Profit	-38.73M	-34.41M	-165.71M	-203.62M	-162.42M
EBITDA	-47.21M	-37.02M	-159.73M	-198.49M	-187.07M
Net Income	-43.49M	-37.07M	-155.94M	-196.88M	-188.99M
Balance Sheet
Total Assets	98.42M	140.60M	213.46M	401.36M	148.13M
Cash, Cash Equivalents and Short-Term Investments	96.16M	138.15M	190.58M	379.45M	116.39M
Total Debt	0.00	0.00	3.95M	1.65M	3.12M
Total Liabilities	20.47M	19.16M	54.99M	83.13M	81.56M
Stockholders Equity	77.94M	121.43M	158.48M	318.23M	66.57M
Cash Flow
Free Cash Flow	-41.99M	-52.54M	-190.97M	-188.43M	-160.27M
Operating Cash Flow	-41.99M	-52.54M	-190.97M	-188.43M	-160.27M
Investing Cash Flow	0.00	101.00K	0.00	0.00	1.00K
Financing Cash Flow	0.00	0.00	-1.68M	450.48M	150.01M

Isofol Medical AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.88
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Negative. The current price of 0.88 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.26, and below the 200-day MA of 1.93, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 33.51 is Neutral, neither overbought nor oversold. The STOCH value of 4.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ISOFOL.

Isofol Medical AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMMU	54 Neutral	kr393.24M	―	-18.79%	―	―	21.85%
Sector *	50 Neutral	kr5.29B	11.97	-82.66%	9.05%	36.04%	27.80%
XBRANE	47 Neutral	kr386.11M	―	-47.73%	―	45.52%	93.35%
ACE	43 Neutral	kr509.35M	―	-138.29%	―	―	39.92%
XINT	43 Neutral	kr282.96M	―		―	5303.85%	55.59%
ISOFOL	36 Underperform	kr236.75M	―	-54.29%	―	-100.00%	-17.35%
GUARD	32 Underperform	€334.78M	―	-205.65%	―	―	24.25%

Isofol Medical AB Corporate Events

Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of the standard 5-FU-based first-line therapy. The trial will proceed in two stages, with the initial phase assessing the benefit/risk profile of escalating doses, followed by a comparison of the highest dose with a lower dose. This milestone marks a significant step towards bringing arfolitixorin closer to market, with the potential to significantly impact treatment outcomes for patients with advanced cancers.

Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the benefit/risk profile and efficacy of arfolitixorin in a new dosing regimen. This milestone marks a significant step in Isofol’s plan to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.

Isofol Medical Begins Phase Ib/II Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of 5-FU-based first-line therapy, with the goal of optimizing treatment outcomes for patients with advanced cancers.

Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy and safety of arfolitixorin in combination with standard 5-FU-based therapy. This milestone is part of Isofol’s strategy to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.

Isofol Medical Begins Phase Ib/II Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the drug’s efficacy and safety in a new dosing regimen, marking a significant milestone in Isofol’s efforts to bring arfolitixorin closer to market, potentially benefiting patients with advanced cancers.

Isofol Medical Initiates Clinical Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study of arfolitixorin, a potential treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to assess the benefit/risk profile of escalating doses in a new dosing regimen, with the goal of optimizing the drug’s efficacy. This milestone marks significant progress in Isofol’s plan to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.

Isofol Medical Initiates Phase Ib/II Study for Colorectal Cancer Treatment

Isofol Medical AB has commenced a clinical phase Ib/II study of its drug candidate arfolitixorin, intended as a new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, will assess the benefit/risk profile of escalating doses and compare efficacy parameters, marking a significant step towards market readiness and potentially offering improved treatment options for patients with advanced cancers.

Isofol Medical Begins Phase Ib/II Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of a 5-FU-based therapy, with the potential to optimize treatment outcomes and bring the drug closer to market, marking a significant milestone for the company.

Isofol Medical Begins Clinical Study for New Cancer Treatment

Isofol Medical AB has initiated a clinical phase Ib/II study for arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the drug’s efficacy as part of standard first-line therapy, marking a significant milestone towards market readiness and offering hope for improved patient outcomes.

Isofol Medical Begins Clinical Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has initiated a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of a standard 5-FU-based therapy, with hopes of improving treatment outcomes for patients with advanced cancers.

Isofol Medical Begins Clinical Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study of arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy of arfolitixorin as part of a standard 5-FU-based therapy. This milestone marks a significant step towards bringing arfolitixorin to market, with expectations of improved treatment outcomes for patients with advanced cancers.

Isofol Medical Initiates Clinical Study for Arfolitixorin in Colorectal Cancer

Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to optimize the drug’s efficacy through a new dosing regimen, marking a significant step towards bringing arfolitixorin to market and potentially improving treatment outcomes for patients with advanced cancers.

Isofol Medical Begins Clinical Study for Colorectal Cancer Drug

Isofol Medical AB has initiated a clinical phase Ib/II study for its drug candidate arfolitixorin, aimed at treating metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, seeks to optimize the dosing regimen to improve efficacy, marking a significant step towards bringing arfolitixorin to market and potentially improving outcomes for patients with advanced cancers.

Isofol Medical Begins Clinical Study of Arfolitixorin for Colorectal Cancer

Isofol Medical AB has initiated a clinical phase Ib/II study of arfolitixorin, a potential new treatment for metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the drug’s efficacy as part of standard 5-FU-based therapy. The trial will assess different dosing regimens to optimize the drug’s effect, marking a significant milestone in Isofol’s efforts to bring arfolitixorin closer to market.